Industry Meeting on Modifying ER/LA Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) – January 25, 2017

Part of the FDA’s Opioid Action plan is to update the REMS requirements for opioids after considering advisory committee recommendations and reviewing existing requirements. The FDA invited all affected sponsors to a meeting on January 25, 2017, to inform them of the Agency’s intention to require a REMS for immediate-release (IR), extended-release (ER), and long-acting (LA) opioid analgesics to ensure the benefits outweigh the risks of misuse, abuse, addiction, overdose, and death.


Page Last Updated: 02/23/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English